Mody Rohit, Nee Sheth Abha Bajaj, Dash Debabrata, Mody Bhavya, Agrawal Ankit, Monga Inderjeet Singh, Rastogi Lakshay, Munjal Amit
Department of Cardiology, Mody Harvard Cardiac Institute & Research Centre, Krishna Super Specialty Hospital, Bathinda, India.
Department of Anatomy, Dr Harvansh Singh Judge Institute of Dental Sciences & Hospital, Panjab University, Chandigarh, India.
Front Cardiovasc Med. 2024 Oct 18;11:1388232. doi: 10.3389/fcvm.2024.1388232. eCollection 2024.
Even with significant advancements in the treatment modalities for patients with heart failure (HF), the rates of morbidity and mortality associated with HF are still high. Various therapeutic interventions, including cardiac resynchronization therapy, Implantable Cardiovascular-Defibrillators, and left ventricular assist devices, are used for HF management. Currently, more research and developments are required to identify different treatment modalities to reduce hospitalization rates and improve the quality of life of patients with HF. In relation to this, various non-valvular catheter-based therapies have been recently developed for managing chronic HF. These devices target the pathophysiological processes involved in HF development including neurohumoral activation, congestion, and left ventricular remodeling. The present review article aimed to discuss the major transcatheter devices used in managing chronic HF. The rationale and current clinical developmental stages of these interventions will also be addressed in this review.
尽管心力衰竭（HF）患者的治疗方式取得了重大进展，但与HF相关的发病率和死亡率仍然很高。包括心脏再同步治疗、植入式心脏除颤器和左心室辅助装置在内的各种治疗干预措施被用于HF的管理。目前，需要更多的研究和开发来确定不同的治疗方式，以降低住院率并提高HF患者的生活质量。与此相关的是，最近已经开发出各种基于非瓣膜导管的疗法来管理慢性HF。这些装置针对HF发展过程中涉及的病理生理过程，包括神经体液激活、充血和左心室重塑。本综述文章旨在讨论用于管理慢性HF的主要经导管装置。这些干预措施的原理和当前临床发展阶段也将在本综述中进行阐述。
